Curated news and analysis on clinical trials, drug approvals, and medical research.
NeuroSense Therapeutics reported that its ALS drug PrimeC achieved a statistically significant 65% reduction in the risk of death in a Phase 2b trial. Separately, the company was granted a South Korean patent covering PrimeC's composition, formulation, and use for ALS treatment through 2042.
Personalized mRNA vaccines showed promise in pancreatic cancer trials with 7 of 16 patients in remission after five years. Stage 2 melanoma patients saw a 50% decreased death risk with personalized mRNA vaccines. U.S. funding cuts and policy shifts have stalled domestic mRNA cancer research while companies move trials abroad.
Colombian authorities confirmed the country's first uncrewed narco sub, a semi-autonomous vessel equipped with Starlink antennas and autopilot systems, was intercepted off Tayrona National Park. The discovery mirrors a broader trend of autonomous smuggling technology proliferating across the Pacific drug highway, where stealth vessels and narco-drones are outpacing enforcement capabilities.
New technologies enhance organoid screening for drug development, including a physics-informed deep learning framework for quantification and an automated electrophysiology system for functional analysis.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Australia's Medical Research Future Fund is investing billions across multiple health research areas, including $100 million for arthritis research over 10 years, AU$22.9 million for dementia projects, and $436 million in 209 grants for Indigenous health research since 2017.
Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Milwaukee County has suspended four detention employees amid a drug smuggling investigation at the Community Reintegration Center, while Cook County Jail has uncovered a new smuggling technique involving narcotics-soaked books mailed from bookstores. Cook County invested over $2 million in detection technology to combat contraband in detention facilities.
Disc Medicine has agreed with the FDA to resubmit bitopertin for rare blood disorder erythropoietic protoporphyria, with the agency allowing the Phase 3 APOLLO trial to support a new filing. The agreement follows a February rejection and could lead to a mid-2027 decision. Disc has implemented workforce cuts and its CFO sold shares amid the regulatory setback.
Advances in precision mental health research include TMS findings published in Nature Molecular Psychiatry showing targeted brain stimulation can address specific depression and anxiety symptoms, the launch of the three-year GlobalMinds NHS genomic study analyzing 49,000 DNA samples, and the new $1 million Wellcome Prize for Mental Health Science.
Newport Police arrested four people after a month-long drug investigation culminated in a search warrant execution. Authorities seized cocaine laced with fentanyl and thousands of dollars in cash. All four suspects are expected in court Wednesday afternoon.
The Arizona Department of Housing awarded $2.5 million in tax credits for the Stone and Speedway Phase I project in Tucson, building 44 affordable units and 12 market-rate units. The $63 million development is the first phase of a two-phase project that will ultimately provide 119 units.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.
